Base Editing Repairs Mutation and Liver Function in Mouse Model of Zellweger Spectrum Disorder

Why It Matters

The study shows that base editing can safely and effectively repair mutations underlying lethal metabolic diseases, paving the way for clinical translation to human patients with Zellweger and similar disorders.

Key Takeaways

• Base editing corrected PEX1 mutation in mice, restoring liver function
• Study used deaminase enzyme previously used in 2025 KJ Muldoon treatment
• Peroxisome activity normalized, indicating potential for human Zellweger therapy
• Research began in 2020, published in Nature Biomedical Engineering
• Demonstrates scalable platform for rare metabolic disorders

Pulse Analysis

Base editing, first described by David Liu in 2016, has evolved from a laboratory curiosity into a therapeutic platform capable of making single‑letter DNA changes without double‑strand breaks. By engineering a more efficient deaminase enzyme, researchers have improved editing precision and reduced off‑target effects, a breakthrough that enabled the first in‑human application for infant KJ Muldoon in 2025. This same enzyme now underpins a study targeting the PEX1 gene, whose loss of function drives Zellweger spectrum disorder, a group of peroxisomal biogenesis defects that cause liver failure, neurodegeneration, and early mortality.

In the mouse model, a single‑base correction restored the activity of peroxisomes, the cellular organelles responsible for breaking down fatty acids and detoxifying metabolites. Treated mice displayed normalized liver enzyme levels and improved histology, indicating that the edited cells regained metabolic competence. The work, initiated in 2020 and now peer‑reviewed, demonstrates that a precise, single‑base edit can translate into organ‑level functional recovery, a critical proof‑of‑concept for moving toward human trials. Importantly, the study confirms that the deaminase component can be repurposed across distinct genetic diseases, highlighting its modularity.

The broader implications extend beyond Zellweger. Successful base editing in a complex, multisystem disorder suggests a viable pathway for tackling other rare metabolic conditions that have eluded conventional gene‑therapy vectors. As regulatory agencies become more comfortable with genome‑editing data, the industry may see accelerated pipelines for bespoke, on‑demand treatments. Investors and biotech firms are watching closely, as the technology promises to unlock a new class of high‑value, low‑incidence therapeutics, potentially reshaping the economics of rare‑disease drug development.